Hogan Lovells advises Engrail Therapeutics on Series A financing extension to US$64 million

Northern California, 4 August 2021 – Global law firm Hogan Lovells advised Engrail Therapeutics on its recently completed US$32 million extension of its Series A financing round, bringing the total to US$64 million for the round.

Engrail Therapeutics is a company focused on the acquisition, development and commercialization of patient-centric therapies for diseases affecting the nervous system. The company will use the proceeds from this round to finance the advancement of its pipeline, including its lead assets, ENX-101, ENX-102, and internal preclinical programs.

The Hogan Lovells team was led by corporate partner Nate Gallon (Silicon Valley) and senior associate Christian Coyne (San Francisco).

You can find out more information in Engrail’s press release.

Back To Listing